What is the latest JUBLPHARMA stock price?
The latest stored price for JUBLPHARMA is Rs 880.35 as of 2026-08-21.
gimli
JUBLPHARMA stock AI analysis
JUBLPHARMA Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
JUBILANT PHARMOVA LTD is a small-cap stock in Healthcare. This Gimli page shows the latest available JUBLPHARMA price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹880.35
1W return
+1.68%
1M return
-12.65%
3M return
-12.98%
6M return
+0.89%
1Y return
-17.48%
Market cap
₹13,943.62 cr
PE
46.09
PB
1.97
ROE
+4.54%
ROCE
+3.88%
RSI
35.74
Turnover
₹20.18 cr
Why it can matter in screens
- Momentum: JUBLPHARMA is below 50DMA, below 200DMA; RSI is 35.74.
- Returns: 1D +1.07%, 1W +1.68%, 1M -12.65%, 3M -12.98%, 1Y -17.48%.
- Trend levels: 52W high ₹1,042.00, 52W low ₹847.85, off high -15.51%.
- Liquidity: latest turnover is ₹20.18 cr; volume vs 20D is +0.83%.
- Valuation/profitability: PE 46.09, PB 1.97, ROE +4.54%, ROCE +3.88%.
- Growth: 3Y sales CAGR +9.76%, 3Y profit CAGR n/a.
Quick Answers
Is JUBLPHARMA above its 50DMA and 200DMA?
JUBLPHARMA is below 50DMA, below 200DMA. The latest 50DMA is 956.50 and the latest 200DMA is 975.14.
What are JUBLPHARMA PE, ROE and ROCE?
JUBLPHARMA has PE 46.09, ROE +4.54%, and ROCE +3.88% in Gimli's latest available snapshot.
How has JUBLPHARMA performed recently?
JUBLPHARMA has returned -12.65% over 1 month, -12.98% over 3 months, and -17.48% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 67.20 cr | 12.10 cr | 7.30 cr | 0.46 |
| 2026-03-31 | 2,272.20 cr | 349.30 cr | 119.40 cr | 7.55 |
| 2025-12-31 | 2,116.10 cr | 270.20 cr | 55.90 cr | 3.52 |
| 2025-09-30 | 1,976.00 cr | 351.20 cr | 119.90 cr | 7.57 |
| 2025-06-30 | 1,878.90 cr | 301.50 cr | 102.90 cr | 6.49 |
| 2025-03-31 | 1,915.80 cr | 353.90 cr | 153.60 cr | 9.71 |
| 2024-12-31 | 1,813.70 cr | 277.40 cr | 100.90 cr | 6.37 |
| 2024-09-30 | 1,742.20 cr | 296.80 cr | 102.80 cr | 6.47 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 8,225.00 cr | 1,266.30 cr | 398.50 cr | 3.97 |
| 2025-03-31 | 7,192.10 cr | 1,589.50 cr | 839.40 cr | 52.99 |
| 2024-03-31 | 6,644.80 cr | 808.80 cr | 77.10 cr | 4.87 |
| 2023-03-31 | 6,219.30 cr | 750.40 cr | -61.00 cr | -3.83 |
| 2022-03-31 | 851.89 cr | 1,150.39 cr | 80.49 cr | 26.00 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 15,522.70 cr | 1,267.10 cr | 3,614.70 cr | 7,095.60 cr |
| 2025-03-31 | 12,756.40 cr | 1,086.20 cr | 2,731.00 cr | 6,238.60 cr |
| 2024-03-31 | 11,548.50 cr | 953.90 cr | 3,664.00 cr | 5,421.10 cr |
| 2023-03-31 | 11,156.70 cr | 1,010.80 cr | 3,676.80 cr | 5,391.80 cr |
| 2022-03-31 | 9,990.87 cr | 980.26 cr | 3,192.00 cr | 5,316.40 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 1,226.80 cr | -222.30 cr | n/a |
| 2025-03-31 | 1,072.10 cr | -43.50 cr | n/a |
| 2024-03-31 | 971.30 cr | 73.60 cr | n/a |
| 2023-03-31 | 660.70 cr | -153.80 cr | n/a |
| 2022-03-31 | 837.54 cr | 237.55 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +47.68% | +15.87% | +12.40% | +8.99% | +23.50% | +6.58% |
| 2026-03-31 | +47.68% | +15.90% | +11.62% | +8.03% | +24.24% | +5.40% |
| 2025-12-31 | +47.68% | +15.96% | +11.22% | +7.69% | +24.57% | +5.40% |
| 2025-09-30 | +47.68% | +16.57% | +10.52% | +7.13% | +24.60% | +5.40% |
| 2025-06-30 | +47.68% | +17.40% | +9.53% | +6.01% | +24.84% | +0.00% |
| 2025-03-31 | +50.68% | +17.22% | +7.05% | +3.66% | +24.50% | +0.00% |
| 2024-12-31 | +50.68% | +16.96% | +6.98% | +3.64% | +24.83% | +0.00% |
| 2024-09-30 | +50.68% | +17.94% | +5.66% | +3.06% | +25.17% | +0.00% |
| 2024-06-30 | +50.68% | +19.49% | +4.07% | +2.25% | +25.18% | +0.00% |
| 2024-03-31 | +50.68% | +19.06% | +3.78% | +2.27% | +25.90% | +0.00% |
| 2023-12-31 | +50.68% | +20.29% | +2.89% | +1.50% | +25.56% | +0.00% |
| 2023-09-30 | +50.68% | +23.21% | +1.65% | +0.42% | +23.88% | +0.00% |
| 2023-06-30 | +50.68% | +23.20% | +1.63% | +0.41% | +23.90% | +0.00% |
| 2023-03-31 | +50.68% | +23.22% | +1.63% | +0.40% | +23.10% | n/a |
| 2022-12-31 | +50.68% | +23.38% | +1.62% | +0.40% | +24.19% | +0.00% |
| 2022-09-30 | +50.68% | +23.06% | +1.61% | +0.39% | +24.59% | +0.00% |
| 2022-06-30 | +50.68% | +0.00% | +24.09% | n/a | n/a | +0.00% |
| 2022-03-31 | +50.68% | +0.00% | +24.08% | n/a | n/a | +0.00% |
| 2021-12-31 | +50.68% | +0.00% | +24.24% | n/a | n/a | +0.00% |
| 2021-09-30 | +50.68% | +0.00% | +24.17% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 456,449.49 cr | 37.677543 | +15.50% | +15.99% |
| DIVISLAB | DIVI S LABORATORIES LTD | 228,223.36 cr | 78.319614 | +18.37% | +42.62% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 165,719.79 cr | 75.983398 | +17.33% | +34.25% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 124,992.04 cr | 63.823550 | +21.03% | +9.67% |
| CIPLA | CIPLA LTD | 115,693.19 cr | 34.304976 | +10.25% | -10.08% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 112,698.21 cr | 22.474914 | +17.93% | +13.61% |
| LUPIN | LUPIN LIMITED | 100,669.80 cr | 14.727517 | +34.34% | +12.19% |
| MANKIND | MANKIND PHARMA LIMITED | 98,418.27 cr | 47.977550 | +13.18% | -8.31% |
Try these prompts
- Analyze JUBILANT PHARMOVA with valuation, momentum and industry peers
- Compare JUBLPHARMA with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare JUBLPHARMA with other Healthcare stocks
Data snapshot: 2026-08-21. Not investment advice.